
ProJenX
ProJenX's mission is to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other neurodegenerative diseases.
Series A ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredAug 12, 2021 (5 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | undisclosed | — | fundraisingfox.com |
Timeline
- Website created
Founders and team
- EFErin Fleming co-founder and Chief Operating Officersource: projenx.com
Companies like ProJenX
AAugustine Therapeutics$85M Series A · Mar 2025
RRougeTx$58M Series A · Oct 2026
RR1 Therapeutics$80.5M Series A · Sep 2026
VVedanta Biosciences$60M Series B+ · Aug 2026
PProtego$130M Series B+ · Dec 2025GGranite Bio$30M Series A · Apr 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/projenx (get a free API key).